About
Therapies for autoimmune disorders
Areas of Focus
Categories
Small Molecule PharmaceuticalBiotech
Team (23)
Andrew Basham
Andrew BashamVP, Legal Affairs
Kezar Life Sciences
team_member
Christopher Kirk, PhD
Christopher Kirk, PhD
Kezar Life Sciences
team_member
Courtney Wallace
Courtney Wallace
Kezar Life Sciences
team_member
Dave Braggs
Dave BraggsVP, Quality Assurance
Kezar Life Sciences
team_member
Elizabeth Garner, MD, MPH
Elizabeth Garner, MD, MPH
Kezar Life Sciences
team_member
Franklin Berger
Franklin Berger
Kezar Life Sciences
team_member
Clinical Trials (8)
View allTotal Trials
8
As Lead Sponsor
7
As Collaborator
1
Total Enrollment
424
By Phase
PHASE2: 6PHASE1: 1PHASE1/PHASE2: 1
By Status
COMPLETED: 5TERMINATED: 1ACTIVE_NOT_RECRUITING: 1WITHDRAWN: 1
Clinical Trials Pipeline8 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT05781750Lead Sponsor
A Study of Zetomipzomib (KZR-616) in Patients with Active Lupus Nephritis (PALIZADE)
PHASE2Terminated
84 participants
Started: Nov 3, 2023 · Completed: Nov 8, 2024
NCT05569759Lead Sponsor
A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)
PHASE2Completed
24 participants
Started: May 23, 2023 · Completed: Apr 30, 2025
NCT05047536Lead Sponsor
KZR-261 in Subjects With Advanced Solid Malignancies
PHASE1Active, not recruiting
61 participants
Started: Sep 30, 2021 · Completed: Dec 31, 2026
NCT04628936Lead Sponsor
Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM.
PHASE2Completed
18 participants
Started: Nov 4, 2020 · Completed: Jun 12, 2023
NCT04039477Lead Sponsor
A Phase 2 Study to Evaluate the Safety and Efficacy of KZR-616 in Patients With AIHA and ITP
PHASE2Withdrawn
Started: Jul 31, 2020 · Completed: Aug 5, 2020
Locations (1)
Headquarters
South SF, CA, United States
Map
Loading map...